US economy grew at brisk 4.2 percent rate in April-June quarter, faster than first estimated Applications for US unemployment benefits dip to 298 K, remain near pre-recession lows From anti-finance crusader to pro-business: France's Hollande shifts stance as economy lags Abercrombie tops 2 Q net income expectations, misses revenue forecasts Dollar General says it still wants to buy Family Dollar after its offer was rejected As fighting continues in Ukraine, global stock markets retreat while gold gets a boost Dollar General meets 2 Q net income expectations, misses revenue forecasts India launches initiative to open millions of zero-balance bank accounts for the poor Alibaba discloses revenue growth is picking up again as Chinese company prepares for big IPO 3 moves health insurers can still make to help steer sick patients away from their plans» Read More
An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.
A prestigious peer-reviewed journal is proposing taking a hardline stance on what it calls the "pervasive" funding relationship between drug and medical device companies and professional medical associations.
Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.
Sure, the market saw some losses today. But that’s a good thing for investors.
There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.
I'm on the road on assignment, but used a little downtime to go through the "Pharma's Market" mailbox. Regarding my farewell to Genentech post yesterday a couple of folks emailed to point out that GENE was Genentech's ticker symbol when it was traded on the Nasdaq back in the day. Then it was GNE on the NYSE before going to the much better DNA.
DNA has always been one of my favorite clever ticker symbols on the biopharma beat. Sure, GENE might've made sense for Genentech if it had been listed on the Nasdaq, but DNA was pretty good. But after today DNA is no more.
Oh, the Dendreon investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge.
All of my, ahem, complaining and whining, to put it politely, about the American Society of Clinical Oncology may not have fallen on deaf ears after all.
Art Levinson and Miles White are "Kings of the Jungle." At least Barron's thinks they are. The weekly investment periodical picked the pair as the only two from biopharma to make its annual list of the "30 Most Respected CEOs."
Management at American International Group's financial products unit asked its employees to let the unit know by 5 p.m. on Monday if they plan to return all or part of the bonuses they got under an employee retention program, said the Wall Street Journal, citing a person familiar with the matter.
My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.
AI G's corporate security advised employees to take measures to increase their safety and security due to "a growing sense of public attention fueled by increased media scrutiny."
Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.
The A.I.G. executive who was nicknamed “Jackpot Jimmy” by a New York tabloid walked up the driveway toward his bay-windowed house in Fairfield, Conn., on Thursday afternoon. "How do I feel?” said the executive, James Haas, repeating the question he had just been asked. “I feel horrible. This has been a complete invasion of privacy," the New York Times reported.
I understand that the government will pay 65 percent of my COBRA payment. Does that mean I should only pay 35 percent of the initial payment?
Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.
All three of President Obama’s top economic advisers were on message when they appeared Sunday on separate television talk shows. Treasury Secretary Timothy F. Geithner, they said, had concluded, based on lawyers’ advice, that he could not stop the $165 million in bonuses that the American International Group was even then doling out to hundreds of employees.
In a stunning development, Sen. Christopher Dodd told CNN that Obama officials asked him to add language to last month's stimulus bill to keep AIG bonuses in place.
Overpaying for our prescription drugs just feels like a headache no one needs right now, doesn’t it?
Get the best of CNBC in your inbox